Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11274390 | 0.86 | PKM (0.52) | PKMBACE1MRGPRX4HSD17B10APP | |
| SCHEMBL11268602 | 0.83 | OXTR (0.49) | MAPTLMNAHPGDALDH1A1GAA | |
| SCHEMBL11510637 | 0.82 | HDAC1 (0.59) | PKMMRGPRX4HSD17B10HDAC1HDAC8 | |
| SCHEMBL23044735 | 0.82 | BACE1 (0.49) | BACE1HSD17B10HDAC1HDAC8HDAC6 | |
| SCHEMBL30643863 | 0.80 | LOXL2 (0.45) | MAPTKDM4EHPGDALDH1A1L3MBTL1 | |
| SCHEMBL20919482 | 0.80 | LOXL2 (0.45) | MAPTKDM4EHPGDALDH1A1L3MBTL1 | |
| SCHEMBL3261173 | 0.79 | ALOX15 (0.56) | PKMMRGPRX4HSD17B10HDAC1HDAC8 | |
| SCHEMBL1519151 | 0.79 | SMN1; SMN2 (0.47) | BACE1HSD17B10APPHDAC1HDAC8 | |
| SCHEMBL23295673 | 0.79 | HTT (0.53) | BACE1HSD17B10APPHDAC6MAPT | |
| SCHEMBL11964451 | 0.79 | HDAC3 (0.49) | BACE1HSD17B10APPHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| CN-1074413-C | Novel benzimidazole derivatives having CGMP-phosphodisterase inhibiting activity | OTSUKA PHARMA CO LTD (JP) | 2001-11-07 | — | — | CN | disclosed |
| EP-0779887-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODIESTERASE INHIBITING ACTIVITY | OTSUKA PHARMA CO LTD (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5998437-A | ARTERIOSCLEROSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0779887-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
| US-4213982-A | USE TO PROMOTE GROWTH RATE OR FEED EFFICIENCY IN LIVESTOCK | E. R. SQUIBB & SONS, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4164498-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, TRANQUILIZERS, SEDATIVES, GROWTH PROMOTERS, ANTICONVULSANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1979-08-14 | — | — | US | disclosed |
| US-4164580-A | 4H-s-Triazolo[4,3-a][1,5]benzodiazepin-5-ones as tranquilizers | E. R. SQUIBB & SONS, INC. (US) | 1979-08-14 | — | — | US | disclosed |
| US-4133809-A | DEPRESSANTS, TRANQUILIZERS, SEDATIVES, GROWTH PROMOTERS, ANTICONVULSANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | PKM 1183/4885BACE1 3281/4885MRGPRX4 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.